SS-31

Accelerating

SS-31 appears in 271 indexed publications going back to 1993, including 54 in the past twelve months. 29 registered trials appear on ClinicalTrials.gov, 1 with Australian sites.

271

Indexed publications

Past 12 months, against 28 the year before

Registered clinical trials

1,502

Monthly readers on Wikipedia, down 5%

On This Figure
Published mostly under the name elamipretide. A mitochondrial context filter removes unrelated SS-31 sample codes.

Research Activity

Publication history

How much work has been indexed each year, from Europe PMC. Momentum is measured over a trailing twelve months rather than calendar years, so a partial current year never reads as a decline.

20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
2015	7
2016	10
2017	13
2018	16
2019	20
2020	21
2021	23
2022	18
2023	19
2024	20
2025	31
2026	49

Public Attention

Who is looking it up

Monthly readers of the SS-31 article on English Wikipedia. An independent measure of curiosity, which often moves quite differently from the evidence.

2025-102026-09

Clinical Trials

The registered pipeline

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

1 trial has a registered Australian site.

Phase distribution across the most recently updated registered trials.

Recruiting·Phase 4
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Stealth BioTherapeutics Inc. · estimated completion 2029-09-30
Active, not recruiting·Phase 3
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics Inc. · estimated completion 2027-08
Completed·Phase 1
FRDA Investigator Initiated Study (IIS) With Elamipretide
Children's Hospital of Philadelphia · completed 2024-06-25
Completed·Phase 3Australian site
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Stealth BioTherapeutics Inc. · completed 2024-09-30
Completed·Phase 2
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Stealth BioTherapeutics Inc. · completed 2022-02-22
Terminated·Phase 3
A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
Stealth BioTherapeutics Inc. · completed 2020-02-10

References

Most recent work

The newest indexed records mentioning SS-31, listed by publication date. Titles are shown as published and link to their source. Inclusion here is a record of what exists, not a judgement of what it shows.

2026-07-10·Bioactive materials
Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis
Li T, Zheng A, Zhu C et al.
2026-10-19·Journal of developmental biology
Report from the 2026 Barth Syndrome Foundation International Scientific, Medical & Family Conference: Advances in Barth Syndrome Research, Therapy Development, and Clinical Care
Marjoram L. et al.
2026-10-14·Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Mitochondrial Quality Control in Degenerative Musculoskeletal Diseases: Signaling Networks and Therapeutic Landscapes
Gao H, Cheng Z, Chen X et al.
2026-10-01·Aging cell
Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging
Zhang HL, Wang Y, Wang C et al.
2026-08-24·Journal of gastroenterology and hepatology
Oral Colon- and Mitochondria-Targeted Nanoparticles Alleviate Ulcerative Colitis by Reeducating Macrophage Polarization via SIRT3/FOXO3a-Mediated Mitochondrial Restoration
Mei R, Zhang R, Li Z et al.
2026-08-12·Journal of controlled release : official journal of the Controlled Release Society
Chondrocyte membrane-camouflaged selenium nanoplatform with dual targeting for mitochondrial restoration and osteoarthritis therapy
Zhang Z, Du Q, Zhu Z et al.
2026-09-17·International journal of molecular sciences
Mitochondrial Quality Control in Inherited Mitochondrial Cardiomyopathy: Convergent Pathobiology and a Testable Therapeutic Framework
Lee CL, Chuang CK, Chang YH et al.
2026-09-01·ACS applied materials & interfaces
Engineered Mitochondria-Targeted Biomimetic Hybrid Nanovesicles Ameliorate Rheumatoid Arthritis via Regulating Macrophage Autophagy and cGAS-STING Signaling
Lu L, Su Y, Zheng L et al.

In the Catalogue

SS-31 available from Polaris Research

SS-31 10mg

Energy & Longevity

$0.89View product

Supplied as research materials for laboratory use. Free express delivery Australia wide.

Sources

Publication data from Europe PMC. Clinical trial data from ClinicalTrials.gov, U.S. National Library of Medicine. Public attention from Wikimedia pageview data. Evidence grades from reptides.co. We report counts and dates from these sources and link every record to its origin, we do not summarise findings. Last synced 2026-10-25.